List of Excipients in Branded Drug VICTOZA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novo Nordisk	VICTOZA	liraglutide	0169-4060	PHENOL	1969-12-31
Novo Nordisk	VICTOZA	liraglutide	0169-4060	PROPYLENE GLYCOL	1969-12-31
Novo Nordisk	VICTOZA	liraglutide	0169-4060	SODIUM PHOSPHATE, DIBASIC, DIHYDRATE	1969-12-31

VICTOZA Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: August 2, 2026

Victoza contains liraglutide, a synthetic GLP-1 receptor agonist formulated as a sterile, aqueous, multidose injection. Its excipient system is simple but technically constrained: phenol provides antimicrobial preservation, propylene glycol supports tonicity and formulation stability, and phosphate controls pH. The largest commercial opportunities are in qualified excipient supply, sterile fill-finish, peptide analytical services, pen-device compatibility, and generic liraglutide manufacturing rather than in novel excipient substitution.

What excipients are used in Victoza?

Victoza is supplied at 6 mg/mL liraglutide in a 3 mL prefilled pen. The formulation contains four principal inactive ingredients:

Component	Function	Commercial relevance
Phenol	Antimicrobial preservative for multidose use	Requires tight control of identity, purity, residual impurities, and container compatibility
Propylene glycol	Tonicity agent and formulation stabilizer	Supports osmolality and peptide stability
Disodium phosphate dihydrate	Buffering agent	Maintains the formulation at approximately pH 8.15
Water for Injection	Vehicle	Requires sterile pharmaceutical-grade supply and validated bioburden control

The approved label identifies liraglutide, phenol, propylene glycol, disodium phosphate dihydrate, and water for injection as the formulation components. Victoza does not contain insulin, albumin, polysorbate, or a lipid excipient. (U.S. Food and Drug Administration [FDA], 2024a)

What is the Victoza formulation composition?

Each milliliter contains 6 mg of liraglutide. A full 3 mL cartridge contains 18 mg of liraglutide. The product is administered once daily at 0.6 mg, 1.2 mg, or 1.8 mg.

The formulation has a relatively high pH for a peptide injection. That creates technical requirements for:

• Peptide chemical stability at alkaline pH
• Control of deamidation and oxidation
• Low particulate formation
• Low adsorption to manufacturing and delivery surfaces
• Compatibility with phenol and propylene glycol
• Stable multidose performance during the in-use period

The label specifies refrigerated storage at 2°C to 8°C before use. After first use, the pen may be stored under permitted conditions for up to 30 days. Victoza must not be frozen or exposed to direct heat or light. (FDA, 2024a)

Why is phenol important in Victoza?

Phenol is the most commercially distinctive excipient in the Victoza formulation. It allows the product to function as a multidose injection by limiting microbial growth after repeated needle penetrations.

Phenol creates several development and manufacturing constraints:

1. The concentration must remain within the approved formulation range.
2. The preservative must remain chemically stable throughout shelf life and the in-use period.
3. Phenol must be compatible with the peptide, elastomeric components, cartridge, and pen injector.
4. The formulation must meet preservative effectiveness and sterility-related requirements.
5. Extractables and leachables from the primary container must remain controlled.

Phenol is a commodity pharmaceutical chemical, so its unit cost is unlikely to determine Victoza economics. The commercial value lies in reliable compendial quality, validated microbial control, low extractables, and supply continuity.

Are there commercial opportunities in phenol supply?

Yes, but the opportunity is qualification-driven rather than based on product differentiation. Suppliers can compete through:

• Multiple qualified manufacturing sites
• Pharmaceutical-grade documentation
• Low trace-metal and impurity profiles
• Stable global inventory
• Regulatory change control
• Support for sterile injectable submissions
• Compatibility data with glass cartridges and elastomeric closures

A supplier entering the Victoza or generic liraglutide market would need to satisfy the finished-dose manufacturer’s supplier qualification process. The ability to provide a regulatory package may be more valuable than a small price reduction.

What role does propylene glycol play in Victoza?

Propylene glycol contributes to tonicity and helps maintain a suitable aqueous environment for liraglutide. It also affects viscosity, water activity, peptide solubility, and interaction with packaging materials.

A generic manufacturer cannot assume that any pharmaceutical-grade propylene glycol will perform identically. Important quality attributes include:

• Assay
• Water content
• Residual solvents
• Aldehydes and related impurities
• Color and appearance
• Bioburden
• Endotoxin profile where applicable
• Container compatibility

Propylene glycol is widely available and generally has low substitution risk. Its commercial opportunity is strongest for suppliers that can provide injectable-grade material with robust documentation and global regulatory support.

What is the function of disodium phosphate in Victoza?

Disodium phosphate dihydrate provides buffering capacity. The formulation is maintained at approximately pH 8.15, which supports liraglutide solubility and stability.

Phosphate selection affects:

• Buffer capacity
• pH drift during storage
• Ionic strength
• Osmolality
• Peptide aggregation behavior
• Compatibility with the primary container and delivery device

A formulation change from disodium phosphate to another phosphate salt, or to a different buffer system, could require comparative stability, degradation, particulate, and device-performance studies. The change may also affect the regulatory pathway for a generic product.

Phosphate is a low-cost excipient with limited stand-alone patent value. Its commercial value is concentrated in supply qualification, batch consistency, and injectable-grade compliance.

What patents protect Victoza and liraglutide?

Victoza’s original active-ingredient protection derived from patents covering liraglutide and related GLP-1 analogues. Novo Nordisk is the principal innovator associated with the Victoza patent estate.

The core U.S. patent most commonly associated with liraglutide is U.S. Patent No. 6,268,343, which covers GLP-1 derivatives including liraglutide. The original term was subject to patent-term adjustment and regulatory exclusivity considerations. Later patents and regulatory protections covered formulations, manufacturing methods, devices, and therapeutic uses.

Patent analysis should distinguish among four categories:

Patent category	Relevance to Victoza
Composition-of-matter patents	Protect liraglutide or related GLP-1 derivatives
Formulation patents	May cover peptide concentration, excipient systems, pH, or stability
Method-of-use patents	May cover treatment of type 2 diabetes or related indications
Device and manufacturing patents	May cover cartridges, pens, peptide production, or fill-finish processes

The relevant commercial question is not whether one core patent expired. It is whether any enforceable patent or regulatory exclusivity blocks a proposed generic product, indication, formulation, or manufacturing process.

What is the Orange Book status of Victoza?

Victoza is an FDA-approved prescription drug product listed in the Orange Book. The Orange Book identifies approved strengths, dosage forms, reference-listed-drug status, patent listings, and any applicable exclusivity information. (FDA, 2024b)

Victoza is an injectable solution in a prefilled pen. Unlike a conventional tablet, an abbreviated new drug application must address more than active-ingredient identity. The applicant must establish pharmaceutical equivalence and demonstrate that the proposed product performs comparably in the delivery system and injectable formulation.

Critical regulatory issues include:

• Same active ingredient, liraglutide
• Same route of administration
• Same dosage form
• Equivalent strength
• Comparable inactive-ingredient profile or adequate justification for differences
• Comparable container-closure system
• Comparable pen functionality
• Adequate in-use stability
• Sterility and particulate control
• Device-use instructions and human-factors considerations

When did Victoza lose exclusivity?

Victoza’s principal composition-of-matter protection was associated with the early 2020s, but the practical loss of market exclusivity depended on patent-term adjustment, pediatric exclusivity, listed patents, litigation, and FDA approval timing.

FDA approved Victoza in 2010 for adults with type 2 diabetes. FDA later expanded its use to pediatric patients aged 10 years and older with type 2 diabetes. That pediatric approval could affect the timing of regulatory exclusivity. (FDA, 2024a)

A generic applicant’s commercial launch date is therefore determined by:

1. The latest enforceable listed patent
2. Any 30-month stay from Paragraph IV litigation
3. Settlement terms
4. FDA approval timing
5. Manufacturing readiness
6. The applicant’s ability to produce a reliable pen-based injectable product

Which companies are challenging Victoza?

Teva Pharmaceuticals has been associated with generic liraglutide development and U.S. regulatory activity. FDA approval of a generic liraglutide product would create a direct competitive pathway against Victoza for the diabetes indication, subject to labeling, patent, and launch restrictions.

The competitive field also includes:

• Novo Nordisk’s own liraglutide products
• Other GLP-1 receptor agonists
• Semaglutide products such as Ozempic and Rybelsus
• Dulaglutide, marketed as Trulicity
• Exenatide products
• Future generic or follow-on liraglutide suppliers

Victoza faces commercial pressure from longer-acting weekly products. A lower-cost generic may still attract demand from payers and patients who need daily liraglutide or who face formulary restrictions on newer GLP-1 products.

What Paragraph IV risks affect generic Victoza?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. For a generic liraglutide applicant, risk areas may include:

• Composition claims
• Formulation claims involving phenol, propylene glycol, or phosphate
• Use claims for type 2 diabetes
• Pen and cartridge claims
• Manufacturing claims covering peptide production
• Patent-term and pediatric-exclusivity calculations

The risk profile is more complex than for a simple small-molecule tablet. Liraglutide is a 31-amino-acid peptide with a fatty-acid side chain. Manufacturing consistency, impurity control, aggregation, and device delivery can create practical barriers even after core compound patents expire.

What formulation patents protect Victoza?

Formulation patents may seek protection for combinations of:

• Liraglutide concentration
• Alkaline pH
• Phenolic preservation
• Propylene glycol
• Phosphate buffering
• Multidose storage
• In-use stability
• Cartridge and pen delivery

The presence of a particular excipient in the approved label does not establish that the excipient itself is patent-protected. Patent scope depends on the claim language. A claim may cover a specific concentration range, pH range, stability result, or combination of components.

For generic developers, the principal strategy is usually to reproduce the reference formulation closely enough to satisfy regulatory requirements while avoiding enforceable claim limitations where necessary. A design-around using a different preservative or buffer could introduce substantial regulatory and stability risk.

How strong is the Victoza patent estate?

The estate has moderate residual strength from a commercial perspective, but its strongest historical protection was the liraglutide composition patent. The practical barrier has shifted from basic molecule exclusivity to manufacturing, device integration, regulatory approval, and market access.

Risk area	Current commercial effect
Core liraglutide patent	Reduced protection after expiration
Formulation patents	Potentially relevant to close-copy products
Method-of-use patents	May restrict specific indications or labeling
Device patents	Can affect pen design and substitution strategy
Manufacturing patents	May require alternative peptide-production routes
Regulatory exclusivity	Can delay approval independent of patent validity
Market competition	Limits pricing power after generic entry

The estate is stronger against a direct, identical pen-and-formulation copy than against a technically differentiated liraglutide product with a legally distinct delivery system.

What manufacturing and IP barriers affect generic liraglutide?

Liraglutide manufacturing is more demanding than conventional small-molecule API production. Key barriers include:

• Peptide synthesis and purification
• Control of deletion sequences and truncated peptides
• Management of oxidation and deamidation products
• Fatty-acid side-chain incorporation
• Removal of process-related impurities
• Control of aggregates and subvisible particles
• Sterile filtration and aseptic filling
• Cartridge filling at low dose volumes
• Pen-device assembly
• In-use stability after repeated dosing
• Cold-chain distribution

The highest-value supplier opportunities are in peptide API manufacturing, specialized analytical testing, sterile fill-finish, and combination-product assembly.

What excipient commercial opportunities exist around Victoza?

Qualified excipient supply

Phenol, propylene glycol, phosphate, and Water for Injection are established materials with limited pricing power. Suppliers can create value through:

• Injectable-grade quality
• Dual sourcing
• Global regulatory files
• Lot-to-lot consistency
• Low impurity levels
• Supply agreements with generic manufacturers

Excipient substitution and formulation design

A new formulation could seek to eliminate phenol, alter the buffer, or modify tonicity. The commercial rationale would include reduced preservative exposure, improved tolerability, longer in-use stability, or compatibility with a different delivery device.

The regulatory burden is significant. A substitute formulation would need evidence that differences in inactive ingredients do not alter safety, efficacy, stability, delivery, or immunogenicity-related risk.

Sterile fill-finish

Liraglutide is suitable for contract manufacturing organizations with:

• Aseptic filling capability
• Cartridge or pen filling lines
• Low-volume precision dosing
• Automated inspection
• Cold-chain handling
• Combination-product quality systems

This is a higher-value opportunity than bulk excipient sales.

Device-compatible packaging

Victoza depends on a multidose prefilled pen. Opportunities include:

• Glass cartridges
• Elastomeric plungers and seals
• Needles
• Dose counters
• Pen mechanisms
• Assembly and labeling
• Extractables and leachables testing

A technically compliant formulation can still fail commercially if the pen has poor dose accuracy, leakage, breakage, needle compatibility, or user-interface performance.

How does Victoza compare with Ozempic and other GLP-1 drugs?

Product	Active ingredient	Dosing frequency	Delivery	Commercial position
Victoza	Liraglutide	Daily	Prefilled pen	Mature diabetes product with generic-entry potential
Ozempic	Semaglutide	Weekly	Prefilled pen	Higher-growth diabetes product
Rybelsus	Semaglutide	Daily	Oral tablet	Oral GLP-1 option
Trulicity	Dulaglutide	Weekly	Prefilled pen	Established weekly injectable
Saxenda	Liraglutide	Daily	Prefilled pen	Weight-management product using related active ingredient

Victoza’s main advantages are established clinical use, known formulation performance, and potential price reduction after generic entry. Its disadvantages are daily dosing, an older device platform, and competition from weekly products with strong commercial adoption.

What revenue exposure does Victoza create for Novo Nordisk?

Victoza revenue is exposed to three structural pressures:

1. Cannibalization by Ozempic and other weekly GLP-1 products
2. Price erosion from generic liraglutide
3. Lower willingness among payers to reimburse a daily legacy product at branded prices

The exposure is concentrated in diabetes markets where Victoza remains reimbursed and where patients or physicians prefer liraglutide. Novo Nordisk can retain value through brand trust, supply reliability, patient support, and portfolio contracting, but the product’s pricing power is weaker than that of newer GLP-1 products.

What generic Victoza launch scenarios are most likely?

Scenario 1: Direct pen-and-formulation competition

A generic manufacturer launches a close formulation and comparable multidose pen. This approach minimizes clinical and regulatory differentiation but carries the highest patent and device-infringement risk.

Scenario 2: Controlled formulation design-around

The manufacturer changes an excipient or device element while preserving the same active ingredient, strength, and route. This may reduce patent risk but increases stability, comparability, and approval risk.

Scenario 3: Limited-channel launch

The manufacturer launches first through selected payers, institutions, or government channels. This approach can reduce launch costs and permit gradual manufacturing scale-up.

Scenario 4: Contract-manufactured generic

A pharmaceutical company commercializes the product while outsourcing peptide API, sterile fill-finish, or pen assembly. This model reduces capital expenditure but increases dependence on qualified suppliers.

What is the geographic coverage of Victoza IP?

The Victoza patent estate has historically included major pharmaceutical markets such as the United States, Europe, Japan, Canada, and other jurisdictions where Novo Nordisk commercialized liraglutide.

Patent expiration and enforcement are jurisdiction-specific. A generic strategy may become commercially viable in one region before another because of differences in:

• Patent term
• Patent-term adjustment
• Supplementary protection certificates
• Pediatric extensions
• Regulatory exclusivity
• Patent litigation
• Local linkage systems
• Government procurement

A global launch requires a country-by-country freedom-to-operate analysis covering the drug substance, formulation, manufacturing process, pen, cartridge, and label.

Key Takeaways

• Victoza is a liraglutide injection containing phenol, propylene glycol, disodium phosphate dihydrate, and Water for Injection.
• Phenol is the key excipient for multidose preservation.
• The formulation operates at approximately pH 8.15 and requires control of peptide degradation and aggregation.
• Excipients are generally low-moat products; qualified injectable supply is the main commercial opportunity.
• Higher-value opportunities exist in peptide API production, sterile fill-finish, pen assembly, and device-compatible packaging.
• Generic entry risk depends on listed patents, Paragraph IV litigation, regulatory exclusivity, device patents, and manufacturing readiness.
• Victoza competes with newer weekly GLP-1 products, particularly semaglutide and dulaglutide.
• The strongest commercial barriers now involve formulation replication, peptide quality, sterile manufacturing, and pen-device integration.

FAQs

Can a generic Victoza product use different excipients?

Yes, but inactive-ingredient differences must be justified under the applicable ANDA requirements. A different preservative or buffer can affect stability, sterility assurance, injection performance, and device compatibility.

Is phenol in Victoza protected by a separate excipient patent?

Phenol itself is not proprietary to Novo Nordisk. Patent risk may arise from claims covering a specific liraglutide formulation containing phenol within a defined concentration or pH range.

Is Victoza a biologic requiring a biosimilar application?

No. Victoza is regulated as a drug product containing the synthetic peptide liraglutide. A competing product would generally pursue an ANDA or another applicable drug pathway rather than a biosimilar application.

What is the most difficult part of manufacturing generic liraglutide?

The most difficult areas are peptide impurity control, fatty-acid side-chain consistency, aggregation control, aseptic filling, and reliable operation of a multidose pen.

Can an excipient supplier sell directly to a Victoza generic manufacturer?

Yes. The supplier would typically need pharmaceutical-grade documentation, quality agreements, change-control procedures, supply continuity, and evidence supporting injectable-product use.

References

1. U.S. Food and Drug Administration. (2024a). Victoza (liraglutide) injection prescribing information. Novo Nordisk A/S.

2. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Patent No. 6,268,343. (2001). Peptide derivatives and pharmaceutical compositions thereof. United States Patent and Trademark Office.

4. U.S. Food and Drug Administration. (2024c). Approved drug products and regulatory exclusivity information. https://www.fda.gov

5. Novo Nordisk A/S. (2024). Annual report 2023. Novo Nordisk.